DrugPatentWatch Database Preview
RUBRACA Drug Profile
When do Rubraca patents expire, and what generic alternatives are available?
Rubraca is a drug marketed by Clovis Oncology Inc and is included in one NDA. There are twelve patents protecting this drug.
This drug has two hundred and forty-six patent family members in fifty-three countries.
The generic ingredient in RUBRACA is rucaparib camsylate. One supplier is listed for this compound. Additional details are available on the rucaparib camsylate profile page.
Summary for RUBRACA
| International Patents: | 246 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 50 |
| Clinical Trials: | 12 |
| Patent Applications: | 58 |
| Drug Prices: | Drug price information for RUBRACA |
| DailyMed Link: | RUBRACA at DailyMed |
Generic Entry Opportunity Date for RUBRACA
Generic Entry Date for RUBRACA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RUBRACA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bristol-Myers Squibb | Phase 1/Phase 2 |
| Anwaar Saeed | Phase 1/Phase 2 |
| Clovis Oncology, Inc. | Phase 1/Phase 2 |
Pharmacology for RUBRACA
| Drug Class | Poly(ADP-Ribose) Polymerase Inhibitor |
| Mechanism of Action | Poly(ADP-Ribose) Polymerase Inhibitors |
Synonyms for RUBRACA
| 283173-50-2 |
| 6H-Azepino(5,4,3-cd)indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)- |
| 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)- |
| 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]- |
| 8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON |
| 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one |
| 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one |
| 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE |
| 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one |
| 8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
| 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
| 8237F3U7EH |
| AC-24390 |
| AG 014699 |
| AG-14447 |
| AG14447 |
| AK317822 |
| AKOS015898427 |
| BCP07633 |
| BDBM50446130 |
| BRD-K88560311-011-01-4 |
| CHEBI:134689 |
| CHEBI:94311 |
| CHEMBL1173055 |
| CS-2785 |
| CTK4G1217 |
| D10079 |
| DB12332 |
| DTXSID10182563 |
| EX-A2700 |
| FT-0696622 |
| GTPL7736 |
| HMABYWSNWIZPAG-UHFFFAOYSA-N |
| HY-10617A |
| I10-0690 |
| KB-73984 |
| Kinome_3180 |
| MolPort-028-744-762 |
| NCGC00263173-01 |
| NCGC00263173-03 |
| NCGC00263173-13 |
| PF 01367338 |
| RPB |
| RUCAPARIB |
| Rucaparib (free base) |
| Rucaparib (USAN/INN) |
| Rucaparib [USAN:INN] |
| Rucaparib; AG 014699; PF-01367338 |
| Rucaparib(AG-014447) |
| SB16538 |
| SCHEMBL844585 |
| Tube725 |
| UNII-8237F3U7EH |
| Z-3241 |
| ZINC25958 |
US Patents and Regulatory Information for RUBRACA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | See Pricing | See Pricing | See Pricing | ||||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | See Pricing | See Pricing | Y | Y | See Pricing | ||
| Clovis Oncology Inc | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RUBRACA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 176013 | See Pricing |
| Georgia, Republic of | P20033055 | See Pricing |
| Japan | 2014001210 | See Pricing |
| European Patent Office | 1633724 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RUBRACA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1633724 | C20150012 00136 | Estonia | See Pricing | PRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014 |
| 1633724 | C01633724/01 | Switzerland | See Pricing | PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: SWISSMEDIC 65160 14.01.2016 |
| 2534153 | CA 2018 00041 | Denmark | See Pricing | PRODUCT NAME: RUCAPARIB CAMSYLATE; REG. NO/DATE: EU/1/17/1250/001-003 20180529 |
| 2534153 | PA2018517 | Lithuania | See Pricing | PRODUCT NAME: RUKAPARIBO KAMSILATAS; REGISTRATION NO/DATE: EU/1/17/1250 20180524 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
